透云生物(01332)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01332 透云生物

已收盘 08-24 14:09:18

0.150

+0.000

0.00%

最高0.150	最低0.150	成交量1,562
今开0.150	昨收0.150	日振幅0.00%
总市值4.21亿	流通市值4.21亿	总股本28.06亿
成交额218.68	换手率0.00%	流通股本28.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01332","market":"HK","secType":"STK","nameCN":"透云生物","latestPrice":0.15,"timestamp":1787551758412,"preClose":0.15,"halted":0,"volume":1562,"delay":0,"changeRate":0,"floatShares":2803662149,"shares":2806000000,"eps":0.0095,"marketStatus":"已收盘","change":0,"latestTime":"08-24 14:09:18","open":0.15,"high":0.15,"low":0.15,"amount":218.68,"amplitude":0,"askPrice":0.155,"askSize":20000,"bidPrice":0.15,"bidSize":260000,"shortable":0,"etf":0,"ttmEps":0.009551,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787621400000},"marketStatusCode":5,"adr":0,"listingDate":1342022400000,"exchange":"SEHK","adjPreClose":0.15,"openAndCloseTimeList":[[1787535000000,1787544000000],[1787547600000,1787558400000]],"volumeRatio":0.001526,"lotSize":10000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01332/tweets","defaultTab":"tweets","newsList":[{"id":"1122709694","title":"透云生物（01332）定于8月28日召开董事会 审议2026年中期业绩及分红方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1122709694","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122709694?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:01","pubTimestamp":1786698066,"startTime":"0","endTime":"0","summary":"透云生物科技集团有限公司（股票代码：01332）14日公告称，公司董事会将于2026年8月28日（星期五）召开会议，主要议程包括：一是批准刊发集团截至2026年6月30日止六个月的中期业绩公告；二是考虑派发中期股息。\n公告显示，董事会成员目前包括执行董事王亮（主席）、周蕊娟（副主席）、杜东；非执行董事陈辉、田宇泽、张乐乐；独立非执行董事张荣平、夏其才、杜成泉。\n公司指出，香港交易及结算所有限公司及香港联合交易所有限公司对本公告内容概不负责，并不就其准确性或完整性作出任何声明。\n市场人士可关注8月28日会议结果，以了解透云生物2026年中期经营表现及现金分配安排的最新信息。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01332"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129964227","title":"透云生物（01332）委任周蕊娟为执行董事兼副主席 月薪10万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1129964227","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129964227?lang=zh_cn&edition=full","pubTime":"2026-08-03 21:02","pubTimestamp":1785762136,"startTime":"0","endTime":"0","summary":"透云生物科技集团有限公司8月3日公告称，董事会已委任周蕊娟为公司执行董事兼副主席，负责公司新材料业务发展，任命自2026年8月3日生效。根据公告，周蕊娟已与公司签订为期三年的服务合约，自2026年8月3日起生效，任何一方可提前一个月书面通知终止。公告还透露，于本公告日期，周蕊娟与公司其他董事、高级管理人员或主要及控股股东之间不存在任何其他关系，亦未持有公司任何证券权益，也未在集团担任其他职务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01332"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183941440","title":"透云生物（01332）公告自2026年8月3日起变更百慕达注册办事处地址","url":"https://stock-news.laohu8.com/highlight/detail?id=1183941440","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183941440?lang=zh_cn&edition=full","pubTime":"2026-08-03 21:01","pubTimestamp":1785762102,"startTime":"0","endTime":"0","summary":"透云生物科技集团有限公司8月3日发布公告称，公司将自2026年8月3日起变更其在百慕达的注册办事处地址。新地址为：Richmond House, 12 Par-la-Ville Road, Hamilton HM 08, Bermuda。原公告未披露旧地址信息。\\n\\n公告同时列示，变更由董事会决议通过并予以公布。\\n\\n公司提示，香港交易及结算所有限公司及香港联合交易所有限公司对本公告内容概不负责，并对其准确性或完整性不作任何声明。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01332"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178055707","title":"透云生物（01332）发布董事会及三大委员会最新成员名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1178055707","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178055707?lang=zh_cn&edition=full","pubTime":"2026-08-03 21:01","pubTimestamp":1785762101,"startTime":"0","endTime":"0","summary":"2026年8月3日，透云生物科技集团有限公司披露最新董事会及其下设委员会成员情况。公告显示，公司董事会由9名董事组成，其中执行董事3名、非执行董事3名、独立非执行董事3名。具体名单及职务如下：。官方公告未披露更多财务数据。本次信息披露主要明确了公司治理结构及各委员会职责分工，进一步规范董事会运作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01332"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656371383","title":"透云生物(01332)：周蕊娟获委任为公司执行董事及副主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2656371383","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656371383?lang=zh_cn&edition=full","pubTime":"2026-08-03 20:47","pubTimestamp":1785761269,"startTime":"0","endTime":"0","summary":"智通财经APP讯，透云生物(01332)发布公告，周蕊娟女士已获委任为公司执行董事及副主席，负责公司新材料业务发展，由2026年8月3日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475448.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1157","01332"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142624481","title":"透云生物7月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1142624481","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142624481?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:32","pubTimestamp":1785749559,"startTime":"0","endTime":"0","summary":"2026年8月3日，透云生物发布截至2026年7月31日止月份的证券变动月报表。报告显示，公司于本期内注册股本维持在125亿股，面值每股为0.04港元，法定注册股本总额500,000,000港元未发生改变。月报显示，截至7月末，公司已发行股份总数与上月底保持一致，分别为2,805,952,149股，无库存股；本期内未发生新增发行、购回或注销股份的变动，股本保持稳定。公司于公告中确认，所有证券发行为及库存股份处理均符合香港联交所《上市规则》及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01332"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193340827","title":"透云生物6月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1193340827","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193340827?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:59","pubTimestamp":1783069146,"startTime":"0","endTime":"0","summary":"透云生物科技集团有限公司于2026年7月3日发布2026年6月30日止月份证券变动月报表。报告显示，公司于本月末的注册股本为12,500,000,000股普通股，每股面值为0.04港元，总面值为5亿港元，较上月底无变化。公司确认其公众持股量符合香港联交所相关规则要求。截至本月末，公司股本保持稳定，尚无购回或注销股份的记录。公司声明已遵守香港联交所《上市规则》及其他相关法律法规。公告由董事王亮签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01332"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184094849","title":"透云生物更新5月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1184094849","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184094849?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:57","pubTimestamp":1780304258,"startTime":"0","endTime":"0","summary":"透云生物于2026年6月1日发布5月股份变动月报表，披露了公司截至2026年5月31日的股本和股份期权变动情况。报告显示，截至期末，公司注册股本保持在12,500,000,000股普通股，面值每股0.04港元，法定注册股本总额为500,000,000港元，与上月底相比无变化。关于股份期权及激励计划，本报告期内，透云生物于2012年5月18日采纳的一项购股权计划中，有302,500股期权已失效，期末该计划尚余600,000股有效期权。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01332"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155467658","title":"透云生物2026年4月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1155467658","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155467658?lang=zh_cn&edition=full","pubTime":"2026-05-04 16:01","pubTimestamp":1777881709,"startTime":"0","endTime":"0","summary":"透云生物科技集团有限公司于2026年5月4日披露截至2026年4月30日的股份变动月报表。本月该公司注册股本与已发行股本整体保持稳定，未发生新增发行或回购行为。截至2026年4月30日，已发行股本总数维持为2,805,952,149股，无库存股份。本月未出现新增发行、购回或注销股份的情况，股本结构保持不变。就股份期权计划而言，期末共有三项购股权计划，合计期权数分别为902,500股、60,200,000股和77,700,000股。第三项购股权计划当月可发行或自库存转让的股份数为25,874,100股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01332"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171655082","title":"透云生物2025年度成功扭亏 业务调整与资产结构同步优化","url":"https://stock-news.laohu8.com/highlight/detail?id=1171655082","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171655082?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:02","pubTimestamp":1776852160,"startTime":"0","endTime":"0","summary":"透云生物于截至2025年12月31日止年度在经营和财务层面均实现重要转变，整体溢利约61.3百万港元，较上一年度的亏损大幅改善，成功扭转连续亏损局面。截至2025年年末，部分董事及委员会成员在任职组成上出现变动，但均按照既定制度完成交接与任命。整体而言，透云生物在本报告期内通过业务聚焦与资产优化实现利润修复，也在治理层面持续完善管理结构，为后续战略升级奠定基础。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"透云生物2025年度成功扭亏 业务调整与资产结构同步优化","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01332"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111014570","title":"透云生物授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1111014570","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111014570?lang=zh_cn&edition=full","pubTime":"2026-04-22 17:56","pubTimestamp":1776851778,"startTime":"0","endTime":"0","summary":"透云生物在最新公告中披露，将于2026年6月5日召开股东周年大会，提呈授予公司董事回购股份的一般授权，额度最高可达通过决议当日已发行股本总数的10%。管理层表示，此举旨在提升股东回报并优化资本结构。公告称，若相关提案在股东大会上获得批准，董事会可于授权期限内在公开市场或其他合适时机执行股份购回。董事会并建议股东留意相关决议事项，将在股东周年大会期间作出正式表决。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"透云生物授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01332"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627848632","title":"透云生物(01332)与深圳大学订立战略合作协议共同开发衣藻格鲁肽项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2627848632","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2627848632?lang=zh_cn&edition=full","pubTime":"2026-04-15 20:14","pubTimestamp":1776255257,"startTime":"0","endTime":"0","summary":"智通财经APP讯，透云生物 发布公告，于2026年4月15日，公司全资附属公司山西透云生物科技有限公司与深圳大学订立科技成果转化战略合作协议。山西透云与深圳大学将就知识产权、藻种管理及保密责任另行订立协议，以确保合作成果得到妥善保护。与深圳大学订立该协议将使集团获得世界领先专利及顶尖合成生物学团队的独家合作机会，确保如衣藻格鲁肽项目等高价值新产品的持续推出。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"透云生物(01332)与深圳大学订立战略合作协议共同开发衣藻格鲁肽项目","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1157","01332"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153355451","title":"透云生物更新3月股份变动月报，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1153355451","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153355451?lang=zh_cn&edition=full","pubTime":"2026-04-01 18:13","pubTimestamp":1775038431,"startTime":"0","endTime":"0","summary":"透云生物科技集团有限公司于2026年4月1日公布了截至2026年3月31日的股份变动月报表。报告显示，本月公司注册股本及已发行股份数保持不变，股本结构整体维持稳定。本月公司法定注册股本仍为12,500,000,000股普通股，面值每股0.04港元，合计注册股本500,000,000港元。公司在报告中确认，经计算其公众持股量符合香港联交所相关规定。公司月报同时显示，报告期内未发生任何购回或注销活动，亦没有新增库藏股或其他股份变动。本次公告由公司董事王亮签署并呈交。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01332"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622587561","title":"透云生物(01332)发布年度业绩，股东应占溢利2679.9万港元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2622587561","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2622587561?lang=zh_cn&edition=full","pubTime":"2026-03-27 23:20","pubTimestamp":1774624853,"startTime":"0","endTime":"0","summary":"智通财经APP讯，透云生物(01332)发布截至2025年12月31日止年度业绩，该集团取得销售所提供货品及服务的收入7194.8万港元，同比减少21.74%;公司拥有人应占溢利2679.9万港元，去年同期则取得亏损8810.7万港元;每股盈利0.95港仙。公告称，年度溢利改善主要主要乃因按公平值计入损益的非持作买卖金融资产的公平值大幅获利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01332","BK1157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622026175","title":"透云生物(01332)发盈喜 预计2025年度溢利不少于5500万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622026175","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2622026175?lang=zh_cn&edition=full","pubTime":"2026-03-25 16:55","pubTimestamp":1774428956,"startTime":"0","endTime":"0","summary":"智通财经APP讯，透云生物(01332)发布公告，集团预期将取得公司截至2025年12月31日止年度溢利不少于5500万港元，而公司于截至2024年12月31日止年度取得亏损约7900万港元。由亏转盈主要归因于集团就非上市及上市股权投资取得按公平值计入损益的金融资产公平值收益约1.29亿港元，而于截至2024年12月31日止年度则取得公平值亏损约3800万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"透云生物(01332)发盈喜 预计2025年度溢利不少于5500万港元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01332","BK1157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185390257","title":"透云生物：预计2025年度净利润不少于0.55亿元，实现扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=1185390257","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185390257?lang=zh_cn&edition=full","pubTime":"2026-03-25 16:52","pubTimestamp":1774428745,"startTime":"0","endTime":"0","summary":"透云生物（01332）3月25日发布正面盈利预告。公司预计，截至2025年12月31日止年度将录得净利润不少于0.55亿元，而上年度同期亏损约0.79亿元，业绩同比实现扭亏为盈。\\n\\n公司指出，业绩反转主要源于非上市及上市股权投资带来的按公平值计入损益的金融资产公平值收益约1.29亿元；相比之下，上一年度同项录得公平值亏损约0.38亿元。\\n\\n透云生物表示，上述数据基于管理层对未审计综合管理账目的初步评估，具体业绩有待审计委员会审阅及进一步更新，最终结果将于2026年3月底或之前正式发布。\\n\\n公司提醒股东及潜在投资者在买卖公司股票时保持审慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01332"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619931198","title":"透云生物(01332.HK)拟3月27日举行董事会会议批准全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2619931198","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2619931198?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:28","pubTimestamp":1773394081,"startTime":"0","endTime":"0","summary":"格隆汇3月13日丨透云生物(01332.HK)宣布，公司将于2026年3月27日(星期五)举行董事会会议，藉以(其中包括)批准刊发公司及其附属公司截至2025年12月31日止年度的全年业绩公告，以及考虑派发末期股息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260313/32066811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01332","BK1157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175575284","title":"透云生物科技（01332）2月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1175575284","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175575284?lang=zh_cn&edition=full","pubTime":"2026-03-02 18:30","pubTimestamp":1772447446,"startTime":"0","endTime":"0","summary":"透云生物科技集团有限公司于2026年3月2日发布2026年2月的证券变动月报表。报告期内，公司法定股本维持在12,500,000,000股普通股，面值每股0.04港元，对应注册资本5亿港元。截至2月28日，已发行股本数量与上月底相同，维持在2,805,952,149股，库存股份为零。截至2月末，公司总股本保持稳定，未发生任何增减变动。公告由公司董事王亮签署，声明所有股份发行及持股变动均遵守相关上市规则与法规的要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01332"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517523331","title":"透云生物拟500万元出售威道国际30%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2517523331","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517523331?lang=zh_cn&edition=full","pubTime":"2025-03-06 20:50","pubTimestamp":1741265431,"startTime":"0","endTime":"0","summary":"格隆汇3月6日丨透云生物公告，于2025年3月6日，卖方与买方已订立出售协议，据此，卖方已同意出售而买方已同意购买目标公司威道国际有限公司股份总数的30%，代价为人民币5,000,000元。尽管目标公司于2024年12月31日录得未经审核负债净额约2,000,000港元，但买方于审阅目标公司的业务及营运状况后，对其未来财务表现抱乐观态度。经考虑集团将收取的代价，董事会认为集团进行出售事项属恰当。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306205038989e9978&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306205038989e9978&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01332","BK1157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517625154","title":"【透云生物(01332.HK)拟500万元出售威道国际有限公司30%股份】透云生物(01332.HK)公布，于2025年3月6日(交易时段后)，公司的直接全资附属APEX CAPITAL BUSINESS LIMITED拟向复兴国际中国有限公司出售威道国际有限公司30%股份，代价为人民币500万元。于完成时，该集团将持有目标公司股份总数的70%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517625154","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517625154?lang=zh_cn&edition=full","pubTime":"2025-03-06 20:50","pubTimestamp":1741265417,"startTime":"0","endTime":"0","summary":"透云生物(01332.HK)公布，于2025年3月6日(交易时段后)，公司的直接全资附属APEX CAPITAL BUSINESS LIMITED拟向复兴国际中国有限公司出售威道国际有限公司30%股份，代价为人民币500万元。于完成时，该集团将持有目标公司股份总数的70%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06205048573545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1157","01332"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chnoe.com","stockEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0},{"period":"3month","weight":0.2397},{"period":"6month","weight":0.2712},{"period":"1year","weight":0.7241},{"period":"ytd","weight":-0.4118}],"compareEarnings":[{"period":"1week","weight":0.0355},{"period":"1month","weight":0.0449},{"period":"3month","weight":0.0158},{"period":"6month","weight":-0.0153},{"period":"1year","weight":0.036},{"period":"ytd","weight":0.0148}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"透云生物科技集团有限公司（原名：中国透云科技集团有限公司）是一家主要从事包装产品生产及销售的投资控股公司。连同其附属公司，该公司通过四个分部运营业务。包装产品分部从事生产及销售钟表盒、珠宝盒、眼镜盒、包装袋及小袋以及陈列用品。二维码业务分部从事提供产品包装上的二维码及解决方案以及广告展示服务。莱茵衣藻产品业务分部从事生产及销售莱茵衣藻、微藻及相关产品。财务投资分部从事证券投资及买卖、放贷、证券经纪及保证金融资。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.041301},{"month":2,"riseRate":0.428571,"avgChangeRate":0.129117},{"month":3,"riseRate":0.285714,"avgChangeRate":0.041216},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.012673},{"month":5,"riseRate":0.214286,"avgChangeRate":-0.110508},{"month":6,"riseRate":0.357143,"avgChangeRate":0.006081},{"month":7,"riseRate":0.5,"avgChangeRate":0.22043},{"month":8,"riseRate":0.466667,"avgChangeRate":0.022053},{"month":9,"riseRate":0.428571,"avgChangeRate":0.009255},{"month":10,"riseRate":0.5,"avgChangeRate":0.187884},{"month":11,"riseRate":0.428571,"avgChangeRate":0.032007},{"month":12,"riseRate":0.571429,"avgChangeRate":0.00295}],"exchange":"SEHK","name":"透云生物","nameEN":"TOUYUN BIOTECH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"透云生物(01332)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供透云生物(01332)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"透云生物,01332,透云生物股票,透云生物股票老虎,透云生物股票老虎国际,透云生物行情,透云生物股票行情,透云生物股价,透云生物股市,透云生物股票价格,透云生物股票交易,透云生物股票购买,透云生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"透云生物(01332)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供透云生物(01332)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}